Introduction: For safe and effective use of antibacterial agents in neonates, specific
knowledge on the pharmacokinetics (PK) and its covariates is needed. This necessitates a …

A dosing chart for amikacin (AMK) was developed from average pharmacokinetic
parameters for infants with varying postnatal ages and birth weights ranging from< 800 to> …

Amikacin plays a key role in the treatment of severe hospital-acquired infections with Gram-
negative bacteria. Therapeutic use of amikacin is challenged by high inter-individual …

Purpose To examine the pharmacokinetics of amikacin and its pharmacokinetic
pharmacodynamic (PKPD) relationship in neonates. To develop an alternative dosing …

OBJECTIVES The primary aim was to compare attainment of goal serum amikacin
concentrations using two dosage regimens in patients admitted to a neonatal intensive care …

Based on a previously derived population pharmacokinetic model, a novel neonatal
amikacin dosing regimen was developed. The aim of the current study was to prospectively …

Abstract Background and Objectives During the newborn period and early infancy, renal
function matures, resulting in changes in the glomerular filtration rate (GFR). This study was …

Aims We aimed to compare the performance of renal function and age as predictors of inter‐
individual variability (IIV) in clearance of amikacin in neonates through parallel development …

Objective: The population pharmacokinetics of amikacin, in neonates, was investigated
using the nonlinear mixed effects model (NONMEM). Methods: One hundred and six steady …

Aim Identify and quantify factors describing variability of amikacin clearance in preterm
neonates at birth. Methods Population pharmacokinetics of amikacin were estimated in a …